$1.83
+0.03 (+1.67%)
Open$1.80
Previous Close$1.80
Day High$1.89
Day Low$1.80
52W High$6.52
52W Low$1.96
Volume—
Avg Volume69.6K
Market Cap19.61M
P/E Ratio—
EPS$-4.59
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+2,155.7% upside
Current
$1.83
$1.83
Target
$41.28
$41.28
$32.58
$41.28 avg
$58.47
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.64M | 1.62M | 1.37M |
| Net Income | -247,177 | -249,222 | -229,259 |
| Profit Margin | -15.1% | -15.4% | -16.8% |
| EBITDA | -331,691 | -310,875 | -283,649 |
| Free Cash Flow | -127,219 | -197,557 | -123,470 |
| Rev Growth | +20.7% | +12.0% | +3.1% |
| Debt/Equity | 0.09 | 0.11 | 0.08 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |